Do you want to know the exact number and position of drug molecules attached to the antibody in your ADC (antibody-drug conjugate)?
Antibody-drug conjugates (ADCs) are site-directed cancer drugs with great potential. They consist of an antibody with one or more cytotoxic drug molecules attached (conjugated) to it. The antibody has a very specific binding to cancer cells. It uses this ability to direct the drug molecule to the exact target of the treatment. Most often, an antibody-drug conjugate is a mixtures of antibodies with 0, 1, 2, 3, or more attached drug molecules in various positions.
Alphalyse offers analytical services in order to determine the exact distribution of drug-to-antibody ratio (DAR) in your antibody-drug conjugate (ADC). We can also determine the exact attachment site(s) of the drug molecule in your ADC.
Our service for determination of DAR distribution includes:
- First, exact masses are determined by UV LC-ESI-MS.
- Then the exact mass distribution of intact ADC is determined.
- We include the exact mass distribution of de-glycosylated ADC.
- You receive calculated DAR distribution in percentage based on MS peak intensity.
Our service for determination of drug molecule attachment sites includes:
- Peptide mapping by nano LC-MS/MS or UV LC-MS/MS.
- Comparison with expected amino acid sequence, including modifications.
- You receive a total sequence coverage map, both for heavy chain and light chain.
- Finally, you receive information about which tryptic peptides are conjugated to the drug molecule.
Innovation collaboration supported by Eurostars.
Alphalyse is collaborating with ChromaCon in Switzerland. Together, we develop purification technologies and analytical services for separation and detailed characterization of antibody-drug conjugate (ADC) with various drug-to-antibody ratio (DAR) distributions. This innovation collaboration is supported by Eurostars.